Figure 7.

GDA transplantation suppresses neurocan and NG2 immunoreactivity. (a) At 4 days after injury, control lesion margins display dense neurocan immunoreactivity (green) mainly associated with fine, GFAP^- processes and to a lesser extent with GFAP⁺ astrocyte cell bodies (red). (b) Neurocan immunoreactivity at 4 days after injury and transplantation is greatly reduced in margins of hPAP⁺ GDA-transplanted lesions. (c) At 8 days after injury and GDA transplantation, neurocan immunoreactivity within lesion margins has increased compared with the 4-day time point. Note, however, that intra-lesion hPAP⁺ GDAs continue not to be immunoreactive to neurocan. (d-f) GDA-transplanted lesion centers (e,f) at 4 days after injury show a marked reduction in NG2 immunoreactivity (red) compared with (d) control lesions. hPAP⁺ cells are stained green. (g-i) Although overall NG2 immunoreactivity has increased within the center of GDA-transplanted lesions (h,i) at 8 days after injury compared with (e,f) the 4-day time point, it is reduced compared with the more uniformly distributed NG2 immunoreactivity within the center of control lesions at 8 days after injury. Scale bars: (a,b,g) 100 μm; (c,h,i) 50 μm; (d-f) 200 μm.